Head-to-head · WeighScore
Eve vs Vaylen
By GLP-1 ScorecardUpdated
Score comparison
Vaylen has the higher recorded score — 77.9/100 to 66.3/100.
Vaylen grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vaylen advertises a $99 monthly semaglutide option. Its annual totals and payment timing differ across the public offer, FAQ and terms.
Before you choose
Eve does not publish a semaglutide price, so its Eve review sets out what it does disclose, while the Vaylen review explains the conditions attached to Vaylen's figure. The semaglutide cost page compares published rates across the field. Ask Eve for a written total before treating either one as the cheaper choice.
If neither one fits, BiltRx vs Eve and FormidableMD vs Vaylen compare each of them with another graded program, and the list of alternatives to Eve ranks the programs closest to Eve on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Collective review covers one graded close to these two, at 71.6/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Eve | Vaylen |
|---|---|---|
| WeighScore | 66.3/100 | 77.9/100 |
| Grade | C | C+ |
| Site position | #206 | #45 |
| Semaglutide | Current price not verified | $99/mo advertised (monthly option; conflicting annual totals) |
| Tirzepatide | Current price not verified | From $99/mo (12-month prepaid equivalent; monthly-plan price not confirmed) |
| Coverage | Confirm coverage for your state | Public disclosures differ between 49 and 50 states |
| Brand-name access | Yes | Not confirmed |
| Oral / sublingual | Not confirmed | Yes |
Strengths
- Homepage lists Wegovy, Ozempic and Mounjaro
- Terms identify Eve Health, Inc. and describe third-party care
What to consider
- Current compounded prices and plan-specific cancellation terms remain unverified
Strengths
- Shows a separate month-to-month semaglutide option
- Advertises injectable and oral compounded options
- Describes cancellation through the patient portal for monthly plans
What to consider
- The annual semaglutide card shows $828 and the FAQ states $996
- The offer and terms describe different payment timing and clinical groups
- Confirm coverage, the dispensing pharmacy and any named branded drug with the provider
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.